InnoCan Pharma (TSE:INNO) has released an update.
InnoCan Pharma has achieved a crucial milestone in veterinary medicine by obtaining an Investigational New Animal Drug (INAD) number from the FDA for its LPT-CBD product, designed for prolonged-release CBD in animal pain management. The FDA’s recognition of InnoCan’s innovative animal drug technology also came with a sponsor fee waiver for the fiscal year 2024, indicating strong support for the company’s ongoing development in this field.
For further insights into TSE:INNO stock, check out TipRanks’ Stock Analysis page.
